These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28408010)

  • 1. Be Careful What You Ask For: Effects of Benefit Descriptions on Diabetes Patients' Benefit-Risk Tradeoff Preferences.
    von Arx LB; Johnson FR; Mørkbak MR; Kjær T
    Value Health; 2017 Apr; 20(4):670-678. PubMed ID: 28408010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding drug preferences, different perspectives.
    Mol PG; Arnardottir AH; Straus SM; de Graeff PA; Haaijer-Ruskamp FM; Quik EH; Krabbe PF; Denig P
    Br J Clin Pharmacol; 2015 Jun; 79(6):978-87. PubMed ID: 25469876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline and 1-year interim follow-up assessment of Japanese patients initiating insulin therapy who were enrolled in the cardiovascular risk evaluation in people with type 2 diabetes on insulin therapy study: an international, multicenter, observational study.
    Kawamori R; Node K; Hanafusa T; Atsumi Y; Naito Y; Oka Y
    Cardiovasc Diabetol; 2013 Sep; 12():131. PubMed ID: 24011395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Factors for Nocturnal Hypoglycemia in Insulin-treated Patients With Type 2 Diabetes: A Secondary Analysis of Observational Data Derived From an Integrated Clinical Trial Database.
    Bae JP; Duan R; Fu H; Hoogwerf BJ
    Clin Ther; 2017 Sep; 39(9):1790-1798.e7. PubMed ID: 28781218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of insulin glargine versus NPH insulin for the treatment of Type 2 diabetes mellitus, modeling the interaction between hypoglycemia and glycemic control in Switzerland.
    Brändle M; Azoulay M; Greiner RA
    Int J Clin Pharmacol Ther; 2011 Mar; 49(3):217-30. PubMed ID: 21329624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact and duration effect of telemonitoring on ΗbA1c, BMI and cost in insulin-treated Diabetes Mellitus patients with inadequate glycemic control: A randomized controlled study.
    Fountoulakis S; Papanastasiou L; Gryparis A; Markou A; Piaditis G
    Hormones (Athens); 2015; 14(4):632-43. PubMed ID: 26188234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
    Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
    Seufert J; Pegelow K; Bramlage P
    Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoglycaemia in the over 75s: Understanding the predisposing factors in type 2 diabetes (T2DM).
    Heald AH; Anderson SG; Cortes GJ; Cholokova V; Narajos M; Khan A; Donnahey G; Livingston M
    Prim Care Diabetes; 2018 Apr; 12(2):133-138. PubMed ID: 28941578
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of an mHealth-enabled hierarchical diabetes management intervention in primary care in China (ROADMAP): A cluster randomized trial.
    Jia W; Zhang P; Zhu D; Duolikun N; Li H; Bao Y; Li X;
    PLoS Med; 2021 Sep; 18(9):e1003754. PubMed ID: 34547030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations of hypoglycemia, glycemic variability and risk of cardiac arrhythmias in insulin-treated patients with type 2 diabetes: a prospective, observational study.
    Andersen A; Bagger JI; Sørensen SK; Baldassarre MPA; Pedersen-Bjergaard U; Forman JL; Gislason G; Lindhardt TB; Knop FK; Vilsbøll T
    Cardiovasc Diabetol; 2021 Dec; 20(1):241. PubMed ID: 34952579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translation of personalized decision support into routine diabetes care.
    Augstein P; Vogt L; Kohnert KD; Heinke P; Salzsieder E
    J Diabetes Sci Technol; 2010 Nov; 4(6):1532-9. PubMed ID: 21129352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Monami M; Candido R; Pintaudi B; Targher G; Mannucci E;
    Nutr Metab Cardiovasc Dis; 2021 Aug; 31(9):2539-2546. PubMed ID: 34158243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What matters in type 2 diabetes mellitus oral treatment? A discrete choice experiment to evaluate patient preferences.
    Mühlbacher A; Bethge S
    Eur J Health Econ; 2016 Dec; 17(9):1125-1140. PubMed ID: 26682548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus.
    Vijan S; Sussman JB; Yudkin JS; Hayward RA
    JAMA Intern Med; 2014 Aug; 174(8):1227-34. PubMed ID: 24979148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of flash glucose monitoring on glycated hemoglobin in type 2 diabetes managed with basal insulin in Canada: A retrospective real-world chart review study.
    Elliott T; Beca S; Beharry R; Tsoukas MA; Zarruk A; Abitbol A
    Diab Vasc Dis Res; 2021; 18(4):14791641211021374. PubMed ID: 34275385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capturing Adult Patient Preferences Toward Benefits and Risks of Second-Line Antihyperglycemic Medications Used in Type 2 Diabetes: A Discrete Choice Experiment.
    Donnan JR; Johnston K; Chibrikov E; Marra CA; Aubrey-Bassler K; Najafzadeh M; Nguyen H; Gamble JM
    Can J Diabetes; 2020 Feb; 44(1):6-13. PubMed ID: 31311729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs.
    Luo M; Kong X; Wang H; Zhai X; Cai T; Ding B; Hu Y; Jing T; Su X; Li H; Ma J
    J Diabetes Res; 2020; 2020():6666403. PubMed ID: 33299890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study.
    Pfohl M; Siegmund T; Pscherer S; Pegelow K; Seufert J
    Vasc Health Risk Manag; 2015; 11():569-78. PubMed ID: 26604774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.